Synta Pharmaceuticals Corp.  

(Public, NASDAQ:SNTA)   Watch this stock  
Find more results for SNTA
-0.022 (-4.89%)
After Hours: 0.428 0.000 (0.00%)
Nov 30, 7:58PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.42 - 0.48
52 week 0.40 - 3.27
Open 0.42
Vol / Avg. 3.27M/2.91M
Mkt cap 61.69M
P/E     -
Div/yield     -
EPS -0.66
Shares 137.79M
Beta 1.17
Inst. own 23%
Nov 5, 2015
Q3 2015 Synta Pharmaceuticals Corp Earnings Release
Oct 21, 2015
Synta Pharmaceuticals Corp Conference Call to Discuss the Outcome of the GALAXY-2 trial
Sep 9, 2015
Synta Pharmaceuticals Corp at FBR Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -73.44% -87.97%
Return on average equity -109.32% -150.86%
Employees 110 -
CDP Score - -


United States - Map
+1-781-2748200 (Phone)
+1-781-2748228 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company focuses on research, development and commercialization of oncology medicines for cancer patients. Its lead oncology drug candidate is ganetespib, which is a heat shock protein 90 (Hsp90) inhibitor. The Company also has an additional clinical-stage oncology candidate: elesclomol, which is a mitochondrial metabolism inhibitor. Ganetespib is a small molecule inhibitor of Hsp90, which is a molecular chaperone required for the folding and activation of cancer-promoting proteins. Elesclomol is a first-in-class investigational drug candidate that triggers programmed cell death (apoptosis) in cancer cells through a mechanism: disrupting cancer cell energy metabolism. The Company entered into a license arrangement for its calcium release-activated calcium channel (CRACM) program, including two candidates and the associated intellectual property portfolio, with PRCL Research Inc. (PRCL).

Officers and directors

Keith R. Gollust Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Chen Schor President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Marc R. Schneebaum Chief Financial Officer, Senior Vice President
Age: 60
Bio & Compensation  - Reuters
Wendy E. Rieder Esq. Senior Vice President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Scott Morenstein Director
Age: 39
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Bruce Kovner Independent Director
Age: 70
Bio & Compensation  - Reuters
Donald W. Kufe M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
William S. Reardon CPA Independent Director
Age: 69
Bio & Compensation  - Reuters